Silver Book Fact

In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.

Rascol, Olivier, David J. Brooks, Amos D. Korczyn, Peter P. DeDeyn, Carl E. Clarke, and Anthony E. Lang, for The 056 Study Group. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa. N Engl J Med. 2000; 342(20): 1484-91. http://content.nejm.org/cgi/content/abstract/342/20/1484

Reference

Title
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa
Publication
N Engl J Med
Publication Date
2000
Authors
Rascol, Olivier, David J. Brooks, Amos D. Korczyn, Peter P. DeDeyn, Carl E. Clarke, and Anthony E. Lang, for The 056 Study Group
Volume & Issue
Volume 342, Issue 20
Pages
1484-91
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • 91 medicines are currently in development for Alzheimer’s disease.  
  • Research breakthroughs that slow the onset and progression of Alzheimer’s disease could achieve annual Medicare savings of $51 billion by 2015, $126 billion by 2025, and $444 billion by 2050.  
  • 32 drugs are currently in development for Parkinson’s disease.  
  • Medicines Allow Patients to Remain Independent Longer: New Alzheimer’s medicine delays need for costly home care  
  • The U.S. Food and Drug Administration has approved five drugs that temporarily improve Alzheimer’s disease symptoms.